IE61112B1 - A process for the manufacture of N,N-(dibenzohexatrienylene) ureas - Google Patents
A process for the manufacture of N,N-(dibenzohexatrienylene) ureasInfo
- Publication number
- IE61112B1 IE61112B1 IE20288A IE20288A IE61112B1 IE 61112 B1 IE61112 B1 IE 61112B1 IE 20288 A IE20288 A IE 20288A IE 20288 A IE20288 A IE 20288A IE 61112 B1 IE61112 B1 IE 61112B1
- Authority
- IE
- Ireland
- Prior art keywords
- acid
- process according
- dibenz
- suspension
- azepine
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 31
- 238000004519 manufacturing process Methods 0.000 title claims description 5
- 235000013877 carbamide Nutrition 0.000 title 1
- 150000003672 ureas Chemical class 0.000 title 1
- XLJMAIOERFSOGZ-UHFFFAOYSA-N cyanic acid Chemical compound OC#N XLJMAIOERFSOGZ-UHFFFAOYSA-N 0.000 claims abstract description 68
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 51
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 48
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 36
- 238000006243 chemical reaction Methods 0.000 claims description 22
- 239000000725 suspension Substances 0.000 claims description 22
- 239000002253 acid Substances 0.000 claims description 20
- ZVCDLGYNFYZZOK-UHFFFAOYSA-M sodium cyanate Chemical compound [Na]OC#N ZVCDLGYNFYZZOK-UHFFFAOYSA-M 0.000 claims description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 18
- 230000002378 acidificating effect Effects 0.000 claims description 17
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- LCGTWRLJTMHIQZ-UHFFFAOYSA-N 5H-dibenzo[b,f]azepine Chemical compound C1=CC2=CC=CC=C2NC2=CC=CC=C21 LCGTWRLJTMHIQZ-UHFFFAOYSA-N 0.000 claims description 13
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 13
- 239000001117 sulphuric acid Substances 0.000 claims description 13
- 235000011149 sulphuric acid Nutrition 0.000 claims description 13
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims description 9
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims description 9
- 239000003960 organic solvent Substances 0.000 claims description 9
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 claims description 8
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 5
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 5
- -1 aliphatic ester Chemical class 0.000 claims description 5
- 239000008096 xylene Substances 0.000 claims description 5
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims description 4
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 claims description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 4
- 239000011707 mineral Substances 0.000 claims description 4
- 239000003791 organic solvent mixture Substances 0.000 claims description 4
- 229930195733 hydrocarbon Natural products 0.000 claims description 3
- 150000002430 hydrocarbons Chemical class 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 125000001931 aliphatic group Chemical group 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 239000004215 Carbon black (E152) Substances 0.000 claims 2
- 238000010306 acid treatment Methods 0.000 claims 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 claims 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 150000001412 amines Chemical class 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004202 carbamide Substances 0.000 abstract 1
- 238000005580 one pot reaction Methods 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 7
- 150000007513 acids Chemical class 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 238000001035 drying Methods 0.000 description 5
- ZFXVFMBOFIEPII-UHFFFAOYSA-N 1h-azepine-4-carboxamide Chemical compound NC(=O)C1=CC=CNC=C1 ZFXVFMBOFIEPII-UHFFFAOYSA-N 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- CVNLBHBYDGUJTF-UHFFFAOYSA-N 11h-benzo[b][1]benzazepine;hydrochloride Chemical compound Cl.C1=CC2=CC=CC=C2NC2=CC=CC=C21 CVNLBHBYDGUJTF-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- OWIKHYCFFJSOEH-UHFFFAOYSA-N Isocyanic acid Chemical compound N=C=O OWIKHYCFFJSOEH-UHFFFAOYSA-N 0.000 description 2
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 2
- 150000003857 carboxamides Chemical class 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000012948 isocyanate Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- GKKCIDNWFBPDBW-UHFFFAOYSA-M potassium cyanate Chemical compound [K]OC#N GKKCIDNWFBPDBW-UHFFFAOYSA-M 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- PXACTUVBBMDKRW-UHFFFAOYSA-N 4-bromobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Br)C=C1 PXACTUVBBMDKRW-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000237858 Gastropoda Species 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 150000008107 benzenesulfonic acids Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- ZFSLODLOARCGLH-UHFFFAOYSA-N isocyanuric acid Chemical compound OC1=NC(O)=NC(O)=N1 ZFSLODLOARCGLH-UHFFFAOYSA-N 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 150000007519 polyprotic acids Polymers 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 230000036632 reaction speed Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010517 secondary reaction Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
- C07D223/22—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
N,N-(dibenzohexatrienylene)urea medicaments can be manufactured in a smooth one-step reaction by reacting a corresponding N,N-(dibenzohexatrienylene)amine with cyanic acid.
[US4847374A]
Description
The invention relates to a process for the manufacture of 5H-dibenz(b,f ]azepine-5-carboxamide, which is characterised in that 5K-dibenz[b,f]azepine (imiraostilbene) is reacted with cyanic acid in an organic solvent or solvent mixture and in the presence of an acidic agent. 5H~Dibenz£b,f ]azepine-5-carboxamide, known by the generic name carbamazepine as an active ingredient in medicaments, is# in accordance with US-PS 2 948 718# usually manufactured by reacting 5H-dibenz[b,f]azepine with phosgene to form 5H-dibenz[b,f )azepine-5-carboxylic acid chloride and by further reaction of the same with ammonia. In accordance with a more recent process according to DE-A1 2 307 174# 5H-dibenz[b,f Jasepine is reacted with an acyl isocyanate and the resulting 5H15 dibenz[b,£]azepine-5-(N-acyl)carboxamide is subjected to basic hydrolysis. The known processes have decided disadvantages. Two separate reaction steps must always be carried out, and in the first step of the process according to the US-PS the use of an, equimolar amount of highly toxic phosgene is unavoidable.
The object of the invention was accordingly to address the hitherto unsolved problem of developing a manufacturing process that in one step results directly in 5E5dibenz [ to, f ] azepine-5-carboxaaide.
The proposed solution according to the invention is surprising in as much as it is known that when 5Hdihenz[b,£]azepine is reacted with alkyl isocyanates it does not form corresponding SH-dibemz [ to ,£ 3 azepine-5- (Sialkyl) carboxamides (DS-Al 2 307 174) and the reaction of N,N~diarylaaines with sodium cyanate and trifluoroacetic acid in benzene could not be used in the case of benzimidazole and carbazole {Chem. and Ind. ISfeS# pages 1428-9)3 The cyanic acid used in accordance with the invention to introduce the 5-carbamoyl group is usually produced by pyrolysis of cyanuric acid, by oxidation of formamide with oxygen with silver or copper contact or by treating ϊ a solution and/or suspension of one of its salts, preferably sodium or potassium cyanate, with an acid» Cyanic acid is not stable in free form. It enters into a large number of polymerisation and autocondensation reactions and in addition readily adds water, alcohols, amines and the like. Solutions thereof in suitable organic solvents are,, however, adequately stable for the purpose of the invention.
The reaction according to the invention is therefore carried out in organic solution, that is to say in an organic solvent or a mixture of organic solvents, cyanic acid preferably being blown into the reaction system in a 'gaseous state, advantageously with an inert gas such as nitrogen or argon, or being freed with the aid of an acid by treating a solution and/or suspension of one of its salts, preferably sodium or potassium cyanate.
Suitable organic solvents are those that do not react with isocyanic acid or that react with isocyanic acid only so slowly that the reaction according to the invention is not impaired by the formation of undesirable intermediates. The following, for example, are suitable: aromatic or araliphatic hydrocarbons, such as benzene or toluene, haloaliphatic compounds, such as 1,2-dicfelorc.ethane, aliphatic carboxylic acids and the aliphatic esters thereof, such as lower alkaaecarboxylic acids, for example acetic acid, or lower alkanecarboxyl ic acid lower alkyl esters, for example ethyl acetate, and also aliphatic ethers, such as diethyl ether, dioxane, tetrahydrofuran and the like, as well as mixtures of the sane. Since cyanic acid enters into undesirable secondary reactions with water? alcohols? amines and the like, the reaction according to the invention is advantageously carried out under essentially aprotic conditions? that is to say? in essentially water-, alcohol- and amine-free organic solution and with the exclusion of water vapour. These precautionary measures can be dispensed with completely? however? when working up the reaction mixture and isolating the addition product formed. o An amount of cyanic acid that is at least equimolar to the amount of 5H-dibenz[b?f ]azepine used is necessary for the reaction according to the invention- To achieve a better reaction yield? however, advantageously from 1..05 to 2.5 times the molar amount? preferably from 1.25 to 2.25 times the molar amount? for example from 1.3 to double the molar amount? of cyanic acid is used, that is to say? a 5 % to 150 %? preferably 25 % to 125 %? for example 30 % to 100 %? excess of cyanic acid is used.
To free cyanic acid from one of its salts, which is an especially preferred embodiment of the invention? in general any protonic acid with an acidic strength sufficient to free cyanic acid from its salts is suitable. The following? for example?' are suitable: mineral acids? for example hydrochloric acid or sulphuric acid, organic sulphonic acids? such as Ci-C^alkanesulphonxc acids or unsubstituted or halo- or Ci-C4alkyl~subetituted benzenesulphonic acids? for example methane-, ethane-? benzene-? p-toluene- or p-bromobenzene-sulphonic acid? or organic carboxylic acids of which the acidic strength in the solvent used corresponds in practice at least to that of formic acid? such as S-mono-? 2,2-di- or 2,2,2tri-halo-Cj-C^alkanoic acids? for example trichloroacetic acid.
The reaction off the 5H-dibenz[b,fJazepine component with cyanic acid is spontaneous and slightly exothermic. The parameters off the reaction are not critical. The reaction can be carried out, for example, in a temperature range of from O’C to 120’C and homogeneously or, preferably, heterogeneously. The reaction is, however, accelerated, and the reaction speed increased, by heating gently and/or by the presence of an acidic agent. The reaction is therefore carried out in the presence of an acidic agent and preferably in a temperature range of from 20c to 120‘C, preferably 100*C. Since the participation of the acidic agent in the reaction is only catalytic, in principle catalytic amounts of acid are sufficient. In general, from 0.01 to 0.15, for example from 0.04 to 0.05, of an equivalent of acidic agent per mol of 5sdibenz[b,f]azepine Is entirely adequate. Only when using polybasic acids of distinctly different acidity stages is It necessary to note in the case off heterogeneous reaction that acidic salts may be precipitated, blocking some of the acid used. When using sulphuric acid, for example, it is therefore necessary to use per mol of 5Hdiben2[b,ffJazepine up to 1.5 mol equivalents, for example from 1.0S to 1.,4 mol equivalents, of sulphuric acid, corresponding to ©-S25 to 0.7 mol, that is to say 5 % to .40 % excess, if using the variant in which cyanic acid Is freed from ©ne of its salts and the reaction is carried out heterogeneously., Obviously, the catalytic acidic agent may alternatively be present or be added in the form of an ammonium salt derived from 5EHdibenJB[b,ff]3 0 asepine.
Suitable acidic agents are, for example, the protonic ' acids indicated above as being suitable for freeing cyanic acid, and also aliphatic carboxylic acids, such as *' Cx-C^alkanoie acids, for example acetic acid, especially if these also act as solvents. Iff the variant in which cyanic acid Is freed in, situ fro® one of its salts is used, then it is generally advantageous to employ a snail excess, that Is an excess of from 0.5 % to 10 %, for example from 1 % to 5 %, of the acid used for freeing cyanic acid but if, for example, sulphuric acid Is used, then, for the reasons mentioned, it is advantageous to employ a 5 I to 40 % excess, for example a 32 % excess.
In a preferred embodiment there is added to a suspension of 5H-dibenz[b,f ]azepine and of 1.75 to 2.25 times the molar amount, for example approximately double the molar amountf of sodium cyanate in toluene, at fro® 20 C to 30’C, for example at from 20 c to 25 ‘c, per mol of sodium cyanate, from 1.005 to 1.05 mol, for example 1.02 mol, of trichloroacetic acid, that is to say a 0.5 % to 5 %, for example a 2 %, excess of trichloroacetic acid, and the whole is heated to from 40’C to 80’C, for example to from 50C to 65C? or there is added to a suspension of 5H~dibenz[b,f jazepine in acetic acid from 1.05 to 1.40 mol equivalents of sulphuric acid, corresponding to from 0.525 mol to 0.7 mol, that Is to say a 5 % to 40 % excess, of sulphuric acid, and there Is then added an amount of sodium cyanate that is at least equimolar to the amount of 5H-dibenz[b,f jazepine used, for example from 1.25 to 1.75 mol, for example 1.6 mol, of sodium cyanate per mol of 5H-dibenz(b,fJazepine, the operation being carried out at from lo'C to 120*C; or there is introduced into a suspension of sodium isocyanate In ethyl acetate fro® 1.02 to 1.1G times the molar amount, for example 1.05, that is to say from 1.04 to 1.06, times the molar amount of hydrogen chloride, that is an excess of from 2 % to 10 %, for example 5 %, that is to say from 4 I to 6 of hydrogen chloride, and there is then added an amount of 5H-dibenzIb,fJazepine that is at most equimolar to the amount of sodium cyanate used, for example a 5 % to 50 % molar deficit, for example from 0,,6 to 0.9 mol, for example 0.75 mol, of 5Πdibenz[b,f]azepine per mol of sodium cyanate, the operation being carried out at from 0G to 80 *C, for example with heating to from 40*C to 70 *c after the addition of th® amine component. \ In another preferred embodiment, there is introduced into a suspension of 5H-dibenz[b,f ]azepine in acetic acid, from 1.25 to 1-75 times the molar amount, preferably from 1.4 to 1.6 times the molar amount, that is to say a 25 % to 75 %, preferably 40 % to 60 %, excess of cyanic acid and the whole is heated, if necessary, to from 25‘c to 50’C; or there is introduced into a suspension of 5E~ dibenz[b,f]azepine in toluene, xylene, 1,2-dichloroethane or ethyl acetate, first of all from 0.01 to 0.15 times the molar amount, for example from 0.01 to 0.12 times the molar amount, that Is to say from 1 to 15 mol §, for example from 1 to 12 mol %, of hydrogen chloride and then from 1.25 to 1.75 times the molar amount, preferably from 1.4 to 1.6 times the molar amount, that is to say a, for example, 25 % to 75 %, preferably 40 % to 60 %, excess of cyanic acid, and the whole is heated, if necessary, to from 50"C to 125'C, for example to from 75 C to 100c.
In a modification of this variant, there is introduced into a suspension of a. mixture of 5H-dibenz[b,f Jazepine and its hydrochloride, for example from 0.8 to 0.96, preferably from 0.85 to 0.95, molar proportions of 5Kdibenz(b,flasepine and from 0»@4 to 0.2, preferably from.·. 0.05 to 0,..15,. iTolar proportions of 5H-dibenz[b,f]azepine hydrochloride (total of molar proportions = 1), from 1.25 to 1.75 times the molar amount, preferably froa 1.4 to 1-6 times the molar amount, that is to say a, for example, 25 % to 75 %, preferably 40 % to 60 %, excess of cyanic acid, and , the whole is heated, if necessary, to from 60 C to lOO’C.
The invention is described in detail in the following Examples., Temperatures are given in degrees Celsius.
Example 1; 723 g of trichloroacetic acid are dissolved in 600 ml of toluene and, in the course of 1 1/2 hours, this solution is added to a suspension of <07 g of 5B-dibenz[b,f]azepine and 290 g of sodium cyanate in 600 al of toluene, the temperature being maintained at 25 "C by cooling.
The whole is then allowed to react for 1/2 hour at 25 C and for 1 hour at 50C, and 1300 ml of water are subsequently slowly added. The mixture is then cooled to 20 C and the product is filtered off, washed with toluene and water and dried at 85-90C jn vacuo. Yield: 475 g of 5Hdibenz[b,f)azepine~5-carboxamide.
Example 2:, 25 g of 5B-dibenz[b,f ]azepine are suspended in ISO ®1 of acetic acid and 14 g of 96 I sulphuric acid are slowly added. 13.5 g of sodium cyanate are added in portions at 30*C while stirring well.
The whole is stirred for 3 hours at 30 C, and the product is filtered off and washed with acetic acid and then with water. 29.5 g of 5B-dibenz[b,f3azepine-5-cartx>xamide are obtained after drying at SOC in vacuo.
.Example 3: 68 g of sodium cyanate are suspended in XOO© ml of ethyl acetate and, while stirring at room temperature, 40 g of hydrogen chloride in gaseous form are introduced. After 4 hours, the sodium chloride that has formed is filtered off and 155 g of 5H-dibenz[brfJ9 azepine are added to the clear filtrate. The reaction mixture is maintained at 50 C for fro® 4 to 5 hours, cooled to 0c and the product is filtered off, washed with a small amount of ethyl acetate and dried at 60 "C in vacuo to yield 177 g of 5H-dibenz[b,f )azepine-5-carbox- ; amide.
Example, 4: 17.4 g of 5H-dibenz[b,f]azepine and 2-3 g of 5H-dibenz[b,fJazepine hydrochloride are suspended in 250 ®1 of toluene. The suspension is heated to ©0' and, in the course of 1 1/2 hours, 6.5 g of monomeric cyanic acid are introduced in a stream of nitrogen and the whole is then heated for a further 1/2 hour at 100’C.
After cooling to 5°, the product is filtered off, washed four times with cold toluene and dried in vacuo at 60*. 18.5 g of 5H"dibenz[b,f]asepine-5-carboxamide are obtained.
Example 5; 17.4 g of 5H-dibenz[b,f]azepine and 2.3 g of 5H-dibenz[b,f ]azepine hydrochloride are suspended in 250 ®.l of xylene (isomeric mixture). At 20"C, 6,.5 g of monomeric cyanic acid are introduced in a stream of nitrogen and the whole is then allowed to react for 4 hours at 30*.
Subsequently, the whole is cooled to O’, and the product is filtered off, washed with xylene and dried in vacuo at 80' to yield 22.1 g of 5H-dibenz[b,£]azepine-5-carbox*amide.
Example. 64 19.3 gof 5H-dibenz[b,f ]azepine are suspended in 200 ml of 1,2-dichloroethane. At 25", first of all 4-5 g of hydrogen chloride and then 6.5 g of cyanic acid y in gaseous form (in a stream of nitrogen) are introduced.
The introduction is carried out for a period of 5 hours and is in several portions. The whole is subsequently allowed to react for 1 hour, and the product is filtered off and washed with 1,2-dichloroethane and then with water.
After drying at 60 ia vapap?-16.0 g of 5H-dibenz[h,f]azepine-5-carboxamide are obtained.
A batch treated in a similar manner was concentrated by evaporation when the reaction was complete and the residue was digested cold with toluene and filtered off. After washing with toluene and water and drying in vacuo at 60’, 22.5 g of 5K-dibenz[b,f ]azepine-5-carboxamide were obtained.
Example 7; 29.0 g of 5H-dibenz[b,f]azepine are suspended in 150 ml of ethyl acetate at 20*. First of all 0.6 g of hydrogen chloride and then 9.7 g of cyanic acid in gaseous for» (in a stream of nitrogen) are introduced.
After stirring for 15 hours at 20 ? the product is filtered off, washed with ethyl acetate and then dried in VAC-DP at 60. 32.0 g of 5H-dibenz[b,f]azepine-5-carboxaaide are obtained.
An analogous test at 50 reaction temperature yielded 29.4 g of 5H-dibenz[b,f )azepine-5-carboxaaide.
Example 8:. 19.3 g of 5H-dibenz[b,f]a2epine are suspended in 2©0 ml of ethyl acetate and 1.0 ml of sulphuric acid (98 %) is added.
At 25'", S.5 g of monomeric cyanic acid (ia a stream of nitrogen) are introduced. The whole is left to stand overnight, then concentrated to dryness by evaporation in vacuo,» and the residue is taken up with toluene. After filtration, washing with toluene and water and drying at 80’ in vacuo. 19.7 g of 5H-dibens[b,f jazepine-S-carbox5 amide are obtained.
Example 9; 19.3 g of 5H-dibenz[b,f]a2epine are heated to 45 with 100 ml of acetic acid. In the course of 1 1/2 hours, 5.5 g of monomeric cyanic acid (in a stream, of nitrogen) are introduced and the whole is left to react for 12 hours at 40°. After cooling to 15\ filtration is carried out followed by washing cold with acetic acid and drying vacuo at 60*.
The resulting crude product is recrystallised from methanol/water (7:3) and yields 19.1 g of SEHdibenz15 [b,f 3azepine-5-carboxamideExample 10: 29.0 g of 5H~dibenz[b,f Jazepine are heated to 45’ in 150 ml of acetic acid- In the course of 1 1/2 hours, 9.7 g of monomeric cyanic acid (in a stream ©£ nitrogen) are introduced and the whole is then allowed to react for 2 hours at 40 and for 12 hours at 20’After the addition of 15 ml of water, the whole is cooled to O* and, after 1 hour, the product is filtered off and washed twice with 15 ml of acetic acid and water to give a crude product which, after recrystallisation from methanol/water (7:3), yields 29.1 g of 5H-dibenz[b,f3asepine-S-earhoxamide.
Claims (5)
1. A process for the manufacture of 5K-dibenz[b,f ]azepine-5*-carboxamide, characterised in that 5K-dibenz~ [b,f] azepine is reacted with cyanic acid in an organic solvent or solvent mixture and In the presence of an acidic agent.
2. A process according to claim 1, characterised in that the organic solvent used is an aliphatic carboxylic acid or an aliphatic ester of such an acid, an aromatic or araliphatic hydrocarbon, a haloaliphatic compound or an aliphatic ether.
3. A process according to either claim 1 or claim 2, characterised in that the organic solvent used is toluene, xylene, 1,2-dichloroethane, acetic acid or ethyl acetate.
4. A process according to either claim x or claim 2, characterised in that cyanic acid Is freed by acid treatment of a solution and/or suspension of a cyanic acid salt in an organic solvent and is used without being isolated5. A process according to claim 3, characterised in that cyanic acid is freed by acid treatment of a solution and/or suspension of a cyanic acid salt in an organic solvent and is used without being isolated. S. A process according to any one of claims 1, 2 and 4, characterised in that the organic solvent used is acetic acid, ethyl acetate or toluene. 7. A precess according to either claim 3 or claim 5, characterised in that the acidic agent used is a mineral
5. 27. 5H-Dibenz(b, f Jazepine whenever manufactured by a, process claimed in a preceding claim.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH27687 | 1987-01-27 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE880202L IE880202L (en) | 1988-07-27 |
| IE61112B1 true IE61112B1 (en) | 1994-10-05 |
Family
ID=4183305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE20288A IE61112B1 (en) | 1987-01-27 | 1988-01-26 | A process for the manufacture of N,N-(dibenzohexatrienylene) ureas |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US4847374A (en) |
| EP (1) | EP0277095B2 (en) |
| JP (1) | JP2587078B2 (en) |
| KR (1) | KR950011119B1 (en) |
| AR (1) | AR243511A1 (en) |
| AT (1) | ATE74353T1 (en) |
| AU (1) | AU607459B2 (en) |
| CA (1) | CA1311476C (en) |
| CY (1) | CY1836A (en) |
| DD (1) | DD270905A5 (en) |
| DE (1) | DE3869633D1 (en) |
| DK (1) | DK169625B1 (en) |
| ES (1) | ES2032052T5 (en) |
| FI (1) | FI88296C (en) |
| GR (1) | GR3004246T3 (en) |
| HK (1) | HK11395A (en) |
| HU (1) | HU202209B (en) |
| IE (1) | IE61112B1 (en) |
| IL (1) | IL85168A (en) |
| MX (1) | MX167129B (en) |
| MY (1) | MY102732A (en) |
| NO (1) | NO169338C (en) |
| NZ (1) | NZ223279A (en) |
| PH (1) | PH25122A (en) |
| PT (1) | PT86611B (en) |
| ZA (1) | ZA88513B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4307181C1 (en) * | 1993-03-08 | 1994-11-10 | Dresden Arzneimittel | Process for the preparation of 5H-dibenz[b,f]azepine-5-carboxamide |
| US7015322B1 (en) * | 1994-07-14 | 2006-03-21 | Degussa Ag | Process for producing carbamazepine |
| RU2124504C1 (en) * | 1994-07-21 | 1999-01-10 | Арцнаймиттельверк Дрезден Гмбх | METHOD OF PREPARING 5H-DIBENZ (b,f) AZEPIN-5-CARBOXAMIDE |
| IT1272897B (en) * | 1995-01-13 | 1997-07-01 | I F C Iniziative Finanziaarie | PROCESS FOR THE PRODUCTION OF 10-OXO-10,11-DIIDRO-SH- -DIBENZ (B, F) AZEPIN-5-CARBOXYAMIDE |
| EP1026158B1 (en) * | 1999-02-08 | 2003-09-24 | Max India Limited | Process for the preparation of 5-carbamoyl-5H-dibenz(b,f)azepine |
| GB0002740D0 (en) * | 2000-02-07 | 2000-03-29 | Novartis Ag | Organic compounds |
| CA2452588C (en) | 2003-12-08 | 2015-05-19 | Shire Pharmaceutical Development Inc. | Methods for the treatment of bipolar disorder using carbamazepine |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2948718A (en) * | 1960-08-09 | New n-heterocyclic compounds | ||
| JPS5681565A (en) * | 1979-10-30 | 1981-07-03 | Ciba Geigy Ag | Manufacture of nnheterocyclic compound |
-
1988
- 1988-01-19 US US07/145,430 patent/US4847374A/en not_active Expired - Lifetime
- 1988-01-21 ES ES88810026T patent/ES2032052T5/en not_active Expired - Lifetime
- 1988-01-21 DE DE8888810026T patent/DE3869633D1/en not_active Expired - Lifetime
- 1988-01-21 EP EP88810026A patent/EP0277095B2/en not_active Expired - Lifetime
- 1988-01-21 IL IL85168A patent/IL85168A/en not_active IP Right Cessation
- 1988-01-21 AT AT88810026T patent/ATE74353T1/en not_active IP Right Cessation
- 1988-01-22 NZ NZ223279A patent/NZ223279A/en unknown
- 1988-01-25 FI FI880320A patent/FI88296C/en not_active IP Right Cessation
- 1988-01-25 CA CA000557228A patent/CA1311476C/en not_active Expired - Lifetime
- 1988-01-25 PT PT86611A patent/PT86611B/en unknown
- 1988-01-25 MX MX010184A patent/MX167129B/en unknown
- 1988-01-26 IE IE20288A patent/IE61112B1/en not_active IP Right Cessation
- 1988-01-26 AR AR88309923A patent/AR243511A1/en active
- 1988-01-26 HU HU88294A patent/HU202209B/en unknown
- 1988-01-26 KR KR88000569A patent/KR950011119B1/en not_active Expired - Lifetime
- 1988-01-26 NO NO880325A patent/NO169338C/en not_active IP Right Cessation
- 1988-01-26 MY MYPI88000062A patent/MY102732A/en unknown
- 1988-01-26 DD DD88312439A patent/DD270905A5/en unknown
- 1988-01-26 DK DK034888A patent/DK169625B1/en not_active IP Right Cessation
- 1988-01-26 ZA ZA880513A patent/ZA88513B/en unknown
- 1988-01-26 JP JP63013738A patent/JP2587078B2/en not_active Expired - Lifetime
- 1988-01-27 AU AU10759/88A patent/AU607459B2/en not_active Expired
- 1988-01-27 PH PH36416A patent/PH25122A/en unknown
-
1992
- 1992-04-02 GR GR910402101T patent/GR3004246T3/el unknown
-
1995
- 1995-01-26 HK HK11395A patent/HK11395A/en not_active IP Right Cessation
- 1995-12-01 CY CY183695A patent/CY1836A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bailey et al. | The Crisscross Addition on Conjugate Systems. The Action of Cyanic Acid, Thiocyanic Acid and Isocyanates on Azines. | |
| KR101148264B1 (en) | Method for the production of 4-4-aminophenyl-3-morpholinon | |
| Bailey et al. | The Use of Cyanic Acid in Glacial Acetic Acid. II. The Addition of Cyanic Acid on Benzalazine. | |
| US5808058A (en) | Process for the preparation of 10-OXO-10, 11-dihydro-5H-dibenz (b,f) azepin-5-carboxamide | |
| IE61112B1 (en) | A process for the manufacture of N,N-(dibenzohexatrienylene) ureas | |
| IE912004A1 (en) | New process for the industrial preparation of¹4-chloro-3-sulfamoyl-n-(2,3-dihydro-2-methyl-1h-indol-1-yl)¹benzamide | |
| US3349099A (en) | Aminoaryl-guanylhydrazones | |
| US3474135A (en) | N-(omega-aminoalkylene)-aminoalkyl sulfonic acids | |
| US5596099A (en) | Process for the preparation of N-(2-sulfatoethyl)-piperazine in high purity | |
| AU732056B2 (en) | Process for making 2-amino-2-imidazoline, guanidine, and 2-amino-3,4,5,6-tetrahydropyrimidine derivatives | |
| US5208351A (en) | Process for the preparation of n-cyanoimidocarbonates | |
| SK279243B6 (en) | Method of 5-carbamoyl-5h-dibenz[b,f]azepine preparation | |
| CZ38298A3 (en) | New imidazoline-2,4-diones containing an ortho-substituted ar (alk) yl radical with an anticonvulsant effect in the 1-position and a process for their preparation | |
| US3578658A (en) | N'-substituted n-arylsulfonyl ureas | |
| SI8810141A (en) | PROCEDURE FOR THE PREPARATION OF N, N- (DIBENZOHEXATRIENYLENE) UREA | |
| US3689649A (en) | N-substituted n-arylsulfonyl ureas for producing a hypoglycaemic effect | |
| JP3558683B2 (en) | Method for producing 5H-dibenz / b, f / azepine-5-carboxamide | |
| US3178406A (en) | Nitrates of s-acymminoimbenzyls | |
| WO1999044996A1 (en) | Process for preparing 3- hydroxy- 5-[(1, 4,5,6- tetrahydro-5-hydroxy- 2- pyrimidinyl)amino]benzoic acid | |
| US3141887A (en) | Process for the preparation of | |
| US3687934A (en) | N{40 -substituted n-arylsulfonyl ureas | |
| CS195707B2 (en) | Method of producing novel n up 4-substituted derivatives of 1,3,4,5-tetrahydro-2h-1,4-benzodiazepine-2-one | |
| US3687935A (en) | 1,2,4,5-tetrahydro-3h-3-benzazepine-3-carbonyl chloride | |
| CN1038128C (en) | Process for manufacture of N,N-(dibenzohexatrienylene) ureas | |
| US3575962A (en) | N'-substituted n-arylsulfonyl ureas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK9A | Patent expired |